IFN-γ-mediated control of SARS-CoV-2 infection through nitric oxide
Copyright © 2023 Silva, Krogstad, Teles, Andrade, Rajfer, Ferrini, Yang, Bloom and Modlin..
Introduction: The COVID-19 pandemic has highlighted the need to identify mechanisms of antiviral host defense against SARS-CoV-2. One such mediator is interferon-g (IFN-γ), which, when administered to infected patients, is reported to result in viral clearance and resolution of pulmonary symptoms. IFN-γ treatment of a human lung epithelial cell line triggered an antiviral activity against SARS-CoV-2, yet the mechanism for this antiviral response was not identified.
Methods: Given that IFN-γ has been shown to trigger antiviral activity via the generation of nitric oxide (NO), we investigated whether IFN-γ induction of antiviral activity against SARS-CoV-2 infection is dependent upon the generation of NO in human pulmonary epithelial cells. We treated the simian epithelial cell line Vero E6 and human pulmonary epithelial cell lines, including A549-ACE2, and Calu-3, with IFN-γ and observed the resulting induction of NO and its effects on SARS-CoV-2 replication. Pharmacological inhibition of inducible nitric oxide synthase (iNOS) was employed to assess the dependency on NO production. Additionally, the study examined the effect of interleukin-1b (IL-1β) on the IFN-g-induced NO production and its antiviral efficacy.
Results: Treatment of Vero E6 cells with IFN-γ resulted in a dose-responsive induction of NO and an inhibitory effect on SARS-CoV-2 replication. This antiviral activity was blocked by pharmacologic inhibition of iNOS. IFN-γ also triggered a NO-mediated antiviral activity in SARS-CoV-2 infected human lung epithelial cell lines A549-ACE2 and Calu-3. IL-1β enhanced IFN-γ induction of NO, but it had little effect on antiviral activity.
Discussion: Given that IFN-g has been shown to be produced by CD8+ T cells in the early response to SARS-CoV-2, our findings in human lung epithelial cell lines, of an IFN-γ-triggered, NO-dependent, links the adaptive immune response to an innate antiviral pathway in host defense against SARS-CoV-2. These results underscore the importance of IFN-γ and NO in the antiviral response and provide insights into potential therapeutic strategies for COVID-19.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Frontiers in immunology - 14(2023) vom: 25., Seite 1284148 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Silva, Bruno J de Andrade [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 03.01.2024 Date Revised 27.03.2024 published: Electronic-eCollection Citation Status MEDLINE |
---|
doi: |
10.3389/fimmu.2023.1284148 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM366532952 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM366532952 | ||
003 | DE-627 | ||
005 | 20240329000327.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240108s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3389/fimmu.2023.1284148 |2 doi | |
028 | 5 | 2 | |a pubmed24n1353.xml |
035 | |a (DE-627)NLM366532952 | ||
035 | |a (NLM)38162653 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Silva, Bruno J de Andrade |e verfasserin |4 aut | |
245 | 1 | 0 | |a IFN-γ-mediated control of SARS-CoV-2 infection through nitric oxide |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 03.01.2024 | ||
500 | |a Date Revised 27.03.2024 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2023 Silva, Krogstad, Teles, Andrade, Rajfer, Ferrini, Yang, Bloom and Modlin. | ||
520 | |a Introduction: The COVID-19 pandemic has highlighted the need to identify mechanisms of antiviral host defense against SARS-CoV-2. One such mediator is interferon-g (IFN-γ), which, when administered to infected patients, is reported to result in viral clearance and resolution of pulmonary symptoms. IFN-γ treatment of a human lung epithelial cell line triggered an antiviral activity against SARS-CoV-2, yet the mechanism for this antiviral response was not identified | ||
520 | |a Methods: Given that IFN-γ has been shown to trigger antiviral activity via the generation of nitric oxide (NO), we investigated whether IFN-γ induction of antiviral activity against SARS-CoV-2 infection is dependent upon the generation of NO in human pulmonary epithelial cells. We treated the simian epithelial cell line Vero E6 and human pulmonary epithelial cell lines, including A549-ACE2, and Calu-3, with IFN-γ and observed the resulting induction of NO and its effects on SARS-CoV-2 replication. Pharmacological inhibition of inducible nitric oxide synthase (iNOS) was employed to assess the dependency on NO production. Additionally, the study examined the effect of interleukin-1b (IL-1β) on the IFN-g-induced NO production and its antiviral efficacy | ||
520 | |a Results: Treatment of Vero E6 cells with IFN-γ resulted in a dose-responsive induction of NO and an inhibitory effect on SARS-CoV-2 replication. This antiviral activity was blocked by pharmacologic inhibition of iNOS. IFN-γ also triggered a NO-mediated antiviral activity in SARS-CoV-2 infected human lung epithelial cell lines A549-ACE2 and Calu-3. IL-1β enhanced IFN-γ induction of NO, but it had little effect on antiviral activity | ||
520 | |a Discussion: Given that IFN-g has been shown to be produced by CD8+ T cells in the early response to SARS-CoV-2, our findings in human lung epithelial cell lines, of an IFN-γ-triggered, NO-dependent, links the adaptive immune response to an innate antiviral pathway in host defense against SARS-CoV-2. These results underscore the importance of IFN-γ and NO in the antiviral response and provide insights into potential therapeutic strategies for COVID-19 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a CD8 lymphocytes | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a T cell response | |
650 | 4 | |a interferon | |
650 | 4 | |a nitric oxide | |
650 | 4 | |a viral immunity | |
650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
650 | 7 | |a EC 3.4.17.23 |2 NLM | |
650 | 7 | |a Interferon-gamma |2 NLM | |
650 | 7 | |a 82115-62-6 |2 NLM | |
650 | 7 | |a Nitric Oxide |2 NLM | |
650 | 7 | |a 31C4KY9ESH |2 NLM | |
700 | 1 | |a Krogstad, Paul A |e verfasserin |4 aut | |
700 | 1 | |a Teles, Rosane M B |e verfasserin |4 aut | |
700 | 1 | |a Andrade, Priscila R |e verfasserin |4 aut | |
700 | 1 | |a Rajfer, Jacob |e verfasserin |4 aut | |
700 | 1 | |a Ferrini, Monica G |e verfasserin |4 aut | |
700 | 1 | |a Yang, Otto O |e verfasserin |4 aut | |
700 | 1 | |a Bloom, Barry R |e verfasserin |4 aut | |
700 | 1 | |a Modlin, Robert L |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 14(2023) vom: 25., Seite 1284148 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2023 |g day:25 |g pages:1284148 |
856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2023.1284148 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2023 |b 25 |h 1284148 |